Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
1.760
+0.055 (3.23%)
At close: May 15, 2025, 4:00 PM
1.750
-0.010 (-0.57%)
After-hours: May 15, 2025, 7:57 PM EDT
Iovance Biotherapeutics Stock Forecast
IOVA's stock price has decreased by -83.58% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 9 professional analysts, the 12-month price target for Iovance Biotherapeutics stock ranges from a low of $4.00 to a high of $25. The average analyst price target of $13.89 forecasts a 689.20% increase in the stock price over the next year.
Price Target: $13.89 (+689.20%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Iovance Biotherapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 4 | 5 | 5 | 5 |
| Buy | 3 | 3 | 4 | 2 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 8 | 9 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $16 → $8 | Strong Buy | Maintains | $16 → $8 | +354.55% | May 12, 2025 |
| Mizuho | Mizuho | Buy Maintains $30 → $10 | Buy | Maintains | $30 → $10 | +468.18% | May 12, 2025 |
| Barclays | Barclays | Buy Maintains $5 → $4 | Buy | Maintains | $5 → $4 | +127.27% | May 12, 2025 |
| JMP Securities | JMP Securities | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | May 9, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $30 → $25 | Strong Buy | Maintains | $30 → $25 | +1,320.45% | May 9, 2025 |
Financial Forecast
Revenue This Year
463.01M
from 164.07M
Increased by 182.20%
Revenue Next Year
750.54M
from 463.01M
Increased by 62.10%
EPS This Year
-0.80
from -1.28
EPS Next Year
-0.33
from -0.80
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 495.3M | 972.4M | 1.4B | ||
| Avg | 463.0M | 750.5M | 1.0B | ||
| Low | 424.1M | 505.0M | 557.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 201.9% | 110.0% | 91.9% | ||
| Avg | 182.2% | 62.1% | 35.6% | ||
| Low | 158.5% | 9.1% | -25.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.64 | 0.02 | 1.05 | ||
| Avg | -0.80 | -0.33 | 0.35 | ||
| Low | -0.93 | -0.65 | -0.08 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.